Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 18;12(1):1699768. doi: 10.1080/19420862.2019.1699768

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Exposure comparison of acMMAE, total antibody and unconjugated MMAE across the eight vc-MMAE ADCs post the first dose of vc-MMAE ADCs at 2.4 mg/kg (90 min intravenous infusion).

Open cycle: observed exposure for each patient, – : mean of exposure, acMMAE: antibody-conjugated MMAE, C_max: maximum concentration, AUC_inf: area under the concentration–time curve from time zero to infinity; ADC1 = Pinatuzumab vedotin (CD22); ADC2 = Polatuzumab vedotin (CD79b); ADC3 = DEDN6526A (ETBR); ADC4 = DMOT4309A (MsLN); ADC5 = DMUC5754A (MUC-16); ADC6 = DNIB0600A (Napi2b); ADC7 = DSTP3086S (Steap1); ADC8 = DFRF4539A (FcRH5).